Midlands Oncology Ltd 12082230 false 2022-08-01 2023-07-31 2023-07-31 The principal activity of the company is oncological services Digita Accounts Production Advanced 6.30.9574.0 true true 12082230 2022-08-01 2023-07-31 12082230 2023-07-31 12082230 bus:Director1 1 2023-07-31 12082230 core:RetainedEarningsAccumulatedLosses 2023-07-31 12082230 core:ShareCapital 2023-07-31 12082230 core:CurrentFinancialInstruments 2023-07-31 12082230 core:CurrentFinancialInstruments core:WithinOneYear 2023-07-31 12082230 core:OtherResidualIntangibleAssets 2023-07-31 12082230 core:FurnitureFittingsToolsEquipment 2023-07-31 12082230 bus:SmallEntities 2022-08-01 2023-07-31 12082230 bus:AuditExemptWithAccountantsReport 2022-08-01 2023-07-31 12082230 bus:FullAccounts 2022-08-01 2023-07-31 12082230 bus:SmallCompaniesRegimeForAccounts 2022-08-01 2023-07-31 12082230 bus:RegisteredOffice 2022-08-01 2023-07-31 12082230 bus:Director1 2022-08-01 2023-07-31 12082230 bus:Director1 1 2022-08-01 2023-07-31 12082230 bus:PrivateLimitedCompanyLtd 2022-08-01 2023-07-31 12082230 core:IntangibleAssetsOtherThanGoodwill 2022-08-01 2023-07-31 12082230 core:OtherResidualIntangibleAssets 2022-08-01 2023-07-31 12082230 core:ComputerEquipment 2022-08-01 2023-07-31 12082230 core:FurnitureFittings 2022-08-01 2023-07-31 12082230 core:FurnitureFittingsToolsEquipment 2022-08-01 2023-07-31 12082230 core:PlantMachinery 2022-08-01 2023-07-31 12082230 countries:AllCountries 2022-08-01 2023-07-31 12082230 2022-07-31 12082230 bus:Director1 1 2022-07-31 12082230 core:OtherResidualIntangibleAssets 2022-07-31 12082230 core:FurnitureFittingsToolsEquipment 2022-07-31 12082230 2021-08-01 2022-07-31 12082230 2022-07-31 12082230 bus:Director1 1 2022-07-31 12082230 core:RetainedEarningsAccumulatedLosses 2022-07-31 12082230 core:ShareCapital 2022-07-31 12082230 core:CurrentFinancialInstruments 2022-07-31 12082230 core:CurrentFinancialInstruments core:WithinOneYear 2022-07-31 12082230 core:OtherResidualIntangibleAssets 2022-07-31 12082230 core:FurnitureFittingsToolsEquipment 2022-07-31 12082230 bus:Director1 1 2021-08-01 2022-07-31 12082230 bus:Director1 1 2021-07-31 iso4217:GBP xbrli:pure

Registration number: 12082230

Midlands Oncology Ltd

Annual Report and Unaudited Financial Statements

for the Year Ended 31 July 2023

 

Midlands Oncology Ltd

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 7

 

Midlands Oncology Ltd

Company Information

Director

Dr R K Dandamudi

Registered office

11c Kingswood Road
Hampton Lovett
Droitwich
Worcestershire
WR9 0QH

Accountants

Ballards LLP
Chartered Accountants
Oakmoore Court
11C Kingswood Road
Hampton Lovett
Droitwich
Worcestershire
WR9 0QH

 

Midlands Oncology Ltd

(Registration number: 12082230)
Balance Sheet as at 31 July 2023

Note

2023
£

2022
£

Fixed assets

 

Intangible assets

4

428

500

Tangible assets

5

4,488

3,556

 

4,916

4,056

Current assets

 

Debtors

6

173,280

110,147

Cash at bank and in hand

 

68,456

-

 

241,736

110,147

Creditors: Amounts falling due within one year

7

(49,001)

(21,430)

Net current assets

 

192,735

88,717

Net assets

 

197,651

92,773

Capital and reserves

 

Called up share capital

100

100

Retained earnings

197,551

92,673

Shareholders' funds

 

197,651

92,773

For the financial year ending 31 July 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 22 March 2024
 

.........................................
Dr R K Dandamudi
Director

   
 

Midlands Oncology Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2023

1

General information

The company is a private company limited by share capital, incorporated in UK.

The address of its registered office is:
11c Kingswood Road
Hampton Lovett
Droitwich
Worcestershire
WR9 0QH
Great Britain

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Midlands Oncology Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2023

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Computer Equipment

33.3% Reducing balance

Fixtures and Fittings

25% Reducing Balance

Plant and Machinery

25% Reducing Balance

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Other intangible assets

10% Straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

 

Midlands Oncology Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2023

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 3 (2022 - 3).

 

Midlands Oncology Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2023

4

Intangible assets

Other intangible assets
 £

Total
£

Cost or valuation

At 1 August 2022

714

714

At 31 July 2023

714

714

Amortisation

At 1 August 2022

214

214

Amortisation charge

72

72

At 31 July 2023

286

286

Carrying amount

At 31 July 2023

428

428

At 31 July 2022

500

500

5

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 August 2022

8,262

8,262

Additions

2,886

2,886

At 31 July 2023

11,148

11,148

Depreciation

At 1 August 2022

4,706

4,706

Charge for the year

1,954

1,954

At 31 July 2023

6,660

6,660

Carrying amount

At 31 July 2023

4,488

4,488

At 31 July 2022

3,556

3,556

 

Midlands Oncology Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2023

6

Debtors

Current

2023
£

2022
£

Other debtors

173,280

110,147

7

Creditors

2023
£

2022
£

Due within one year

Other creditors

49,001

21,430

8

Related party transactions

Transactions with the director

2023

At 1 August 2022
£

Advances to director
£

Repayments by director
£

At 31 July 2023
£

Dr R K Dandamudi

110,147

246,055

(182,924)

173,279

         
       

 

2022

At 1 August 2021
£

Advances to director
£

Repayments by director
£

At 31 July 2022
£

Dr R K Dandamudi

35,321

111,794

(36,968)

110,147